Andrew Victor Schally – Nobel Prize Winner in Medicine, Legend and Pioneer in Endocrinology and a Great Friend and Supporter of the TransCampus

Fig. 1 Prof. Andrew Schally.

Prof. Dr. Andrew Schally, who almost reached the age of 100, has passed away. He was a pioneer in the field of endocrinology and metabolism. His discovery, together with Prof. Roger Guillemin and Prof. Samuel McCann, of the hypothalamic releasing hormones, has profoundly shaped our understanding of the regulatory circuits and feedback mechanisms in modern endocrinology. This breakthrough has revolutionized our approach to diagnosing and treating endocrine and endocrine-related diseases. Beyond endocrinology and metabolism, he has pioneered the modern therapy of prostate cancer. In addition to discovering hypothalamic releasing hormones, he led an outstanding team of protein and peptide chemists to develop numerous agonists and antagonists, allowing us to define and understand the crucial role of central releasing hormones in almost all key metabolic processes in the healthy organisms and in disease.

Publication History

Article published online:
09 December 2024

• References

• 1 Balyura M, Gelfgat E, Ehrhart-Bornstein M. et al. Transplantation of bovine adrenocortical cells encapsulated in alginate. Proc Natl Acad Sci USA 2015; 112: 2527-2532
• 2 Belavgeni A, Bornstein SR, von Massenhausen A. et al. Exquisite sensitivity of adrenocortical carcinomas to induction of ferroptosis. Proc Natl Acad Sci USA 2019; 116: 22269-22274
• 3 Belavgeni A, Maremonti F, Tonnus W. et al. vPIF-1 is an insulin-like antiferroptotic viral peptide. Proc Natl Acad Sci U S A 2023; 120: e2300320120
• 4 Granata R, Leone S, Zhang X. et al. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2024 in press
• 5 Ludwig B, Barthel A, Reichel A. et al. Modulation of the pancreatic islet-stress axis as a novel potential therapeutic target in diabetes mellitus. Vitam Horm 2014; 95: 195-222
• 6 Ludwig B, Ludwig S, Steffen A. et al. Favorable outcome of experimental islet xenotransplantation without immunosuppression in a nonhuman primate model of diabetes. Proc Natl Acad Sci U S A 2017; 114: 11745-11750
• 7 Ludwig B, Reichel A, Steffen A. et al. Transplantation of human islets without immunosuppression. Proc Natl Acad Sci U S A 2013; 110: 19054-19058
• 8 Ludwig B, Rotem A, Schmid J. et al. Improvement of islet function in a bioartificial pancreas by enhanced oxygen supply and growth hormone releasing hormone agonist. Proc Natl Acad Sci U S A 2012; 109: 5022-5027
• 9 Ludwig B, Ziegler CG, Schally AV. et al. Agonist of growth hormone-releasing hormone as a potential effector for survival and proliferation of pancreatic islets. Proc Natl Acad Sci U S A 2010; 107: 12623-12628
• 10 Schmid J, Ludwig B, Schally AV. et al. Modulation of pancreatic islets-stress axis by hypothalamic releasing hormones and 11beta-hydroxysteroid dehydrogenase. Proc Natl Acad Sci U S A 2011; 108: 13722-13727
• 11 Schubert U, Schmid J, Lehmann S. et al. Transplantation of pancreatic islets to adrenal gland is promoted by agonists of growth-hormone-releasing hormone. Proc Natl Acad Sci U S A 2013; 110: 2288-2293
• 12 Steenblock C, Rubin de Celis MF, Delgadillo Silva LF. et al. Isolation and characterization of adrenocortical progenitors involved in the adaptation to stress. Proc Natl Acad Sci U S A 2018; 115: 12997-13002
• 13 Zhang X, Cui T, He J. et al. Beneficial effects of growth hormone-releasing hormone agonists on rat INS-1 cells and on streptozotocin-induced NOD/SCID mice. Proc Natl Acad Sci U S A 2015; 112: 13651-13656
• 14 Ziegler CG, Brown JW, Schally AV. et al. Expression of neuropeptide hormone receptors in human adrenal tumors and cell lines: antiproliferative effects of peptide analogues. Proc Natl Acad Sci U S A 2009; 106: 15879-15884
• 15 Ziegler CG, Ullrich M, Schally AV. et al. Anti-tumor effects of peptide analogs targeting neuropeptide hormone receptors on mouse pheochromocytoma cells. Mol Cell Endocrinol 2013; 371: 189-194